Market Update (NYSE:AGN): Allergan Announces FDA Approves Revised Indication for OZURDEX® (dexamethasone intravitreal implant) 0.7 mg for the Treatment of Diabetic Macular Edema

[Business Wire] – Allergan, Inc., announced today that the U.S. Food and Drug Administration has approved OZURDEX® 0.7 mg, a sustained-release biodegradable steroid implant, for the treatment of diabetic macular edema . Read . . . → Read More: Market Update (NYSE:AGN): Allergan Announces FDA Approves Revised Indication for OZURDEX® (dexamethasone intravitreal implant) 0.7 mg for the Treatment of Diabetic Macular Edema Similar Articles: Market Update (NYSE:AGN): Allergan Issues Statement Regarding Recent Valeant Correspondence Company Update (NYSE:AGN): Allergan Provides Update on Written Requests from Pershing Square Regarding Special Meeting of Stockholders Stock Update (NYSE:AGN): Allergan Announces OZURDEX® (dexamethasone 700 mcg intravitreal implant in applicator) Now Approved in the European Union for the Treatment of Diabetic Macular Edema